TRACK6 (iii): Therapeutic Targets in Cancer
6(iv): Clinical Research in Cancer Immunology
JCST 2011/S9: 1948-5956-10000S9-1/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Targeting superoxide dismutase 1 for chemosensitization of platinum resistant ovarian
cancer cells Mu Wang
JCST 2011/S9: 1948-5956-10000S9-2/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Unresolved infl ammation: Immune dynamics of aging process and tumorigenesis Mahin Khatami
JCST 2011/S9: 1948-5956-10000S9-3/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 IPMN of the pancreas - Evaluation of pathohistological subtypes and clinical outcome Marius Distler
JCST 2011/S9: 1948-5956-10000S9-4/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Using GlycoExpress for production of highly active antibodies directed against novel
and existing targets Steffen Goletz
JCST 2011/S9: 1948-5956-10000S9-5/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 BiTE Antibodies for Cancer Therapy Patrick A. Baeuerle and Roman Kischel
JCST 2011/S9: 1948-5956-10000S9-6/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Lactobacillus casei ssp.casei could induce the Th1 cytokine production and Natural
Killer cells activity in BALB/c mice bearing invasive ductal carcinoma Mohammad Mehdi Soltan Dallal, Mohammad Hossein Yazdi, Marzieh Holakuyee, Zuhair Mohammad Hassan, Abbas Mirshafiey
and Mehdi Mahdavi
JCST 2011/S9: 1948-5956-10000S9-7/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Clinical Pharmacokinetics of Cisplatin in Patients with Malignant Tumor of Limb
(MAL) by Hyperthermic Antiblastic Perfusion (HAP) Treatment Jianshi Lou, Jing Zhu and Zhiqing Cui
JCST 2011/S9: 1948-5956-10000S9-8/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Impaired cytolytic function of natural killer (NK) cells obtained from patients with head
and neck cancer can be partially restored by the triggering of toll-like receptor 3 (TLR3)
expressed on NK cells Miroslaw J. Szczepanski
JCST 2011/S9: 1948-5956-10000S9-9/Special Issue 2011
doi: 10.4172/1948-5956.10000S9 Targeted and image-guided cancer treatment using Theranostic nanoparticles Lily Yang